Latest news

FDA is Mind-Numbing America: Psychotropic Drugs and Electroshock Approval Boosts $35B Industry

brain-drugs

 

READ MORE AT HEALTH IMPACT NEWS 

By CCHR International
The Mental Health Industry Watchdog

Excerpts:

The Food and Drug Administration (FDA) is considering approving Johnson & Johnson’s (J&Js) new nasal spray antidepressant, esketamine (Spravato[1]) after an FDA advisory committee voted on February 12, 2019 in its favor.[2]

The drug is a chemical mirror of ketamine, a potent “dissociative anesthetic” that is abused as the illegal “club drug,” Special K, and generates an intense high and euphoric effects, and hallucinations.… Read More